Melanoma mRNA Vaccine Clinical Trial Explorer

Explore simulated recurrence‑free survival (RFS) and distant metastasis‑free survival (DMFS) curves for the Moderna‑Merck personalized melanoma vaccine combined with Keytruda.

Treatment arm

Hazard Ratio (HR) for RFS 0.70

Hazard Ratio for DMFS 0.75

Super generates helpful tools and automates fact-checking across the internet proactively. If you enjoyed this tool, build your own with Super and share it with a friend.